{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:36:03Z","timestamp":1770230163207,"version":"3.49.0"},"reference-count":33,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mirt"],"DOI":"10.4274\/mirt.galenos.2025.92259","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T14:21:21Z","timestamp":1770128481000},"source":"Crossref","is-referenced-by-count":0,"title":["Quantitative characterization of 18F-PSMA-1007 and [68Ga]Ga-PSMA-11 PET-CT Imaging in Suspected Prostate Cancer: A Single-centre Experience"],"prefix":"10.4274","author":[{"given":"Bal","family":"Sanghera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerry","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Sanghera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai Lup","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Tan EH, Burn E, Barclay NL, Delmestri A, Man WY, Golozar A, Serrano \u00c0R, Duarte-Salles T, Corn-ford P, Prieto Alhambra D, Newby D; OPTIMA Consortium. Incidence, prevalence, and survival of prostate cancer in the UK. JAMA Netw Open. 2024;7:e2434622.","DOI":"10.1001\/jamanetworkopen.2024.34622"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"683793","DOI":"10.3389\/fonc.2021.683793","article-title":"The evolving role of 18F-FDG PET\/CT in diag-nosis and prognosis prediction in progressive prostate cancer","volume":"11","author":"Shen","year":"2021","unstructured":"2. Shen K, Liu B, Zhou X, Ji Y, Chen L, Wang Q, Xue W. The evolving role of 18F-FDG PET\/CT in diag-nosis and prognosis prediction in progressive prostate cancer. Front Oncol. 2021;11:683793.","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"832747","DOI":"10.3389\/fonc.2022.832747","article-title":"Editorial: exploring the potential of PSMA-PET imaging on personalized prostate cancer treatment","volume":"12","author":"Ilhan","year":"2022","unstructured":"3. Ilhan H, Royce T, Qiu X, Zamboglou C. Editorial: exploring the potential of PSMA-PET imaging on personalized prostate cancer treatment. Front Oncol. 2022;12:832747.","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","article-title":"Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer-a systematic review and meta-analysis","volume":"27","author":"Huang","year":"2024","unstructured":"4. Huang S, Ong S, McKenzie D, Mirabelli A, Chen DC, Chengodu T, Murphy DG, Hofman MS, Law-rentschuk N, Perera M. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2024;27:654-664.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"102699","DOI":"10.1016\/j.ctrv.2024.102699","article-title":"177Lu-PSMA therapy in metastatic prostate cancer: an updated review of prognostic and predictive biomarkers","volume":"125","author":"Giunta","year":"2024","unstructured":"5. Giunta EF, Brighi N, Gurioli G, Matteucci F, Paganelli G, De Giorgi U. 177Lu-PSMA therapy in metastatic prostate cancer: an updated review of prognostic and predictive biomarkers. Cancer Treat Rev. 2024;125:102699.","journal-title":"Cancer Treat Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1055\/a-1659-0010","article-title":"[18F]DCFPyL PET\/CT for imaging of prostate cancer","volume":"61","author":"Rowe","year":"2022","unstructured":"6. Rowe SP, Buck A, Bundschuh RA, Lapa C, Serfling SE, Derlin T, Higuchi T, Gorin MA, Pomper MG, Werner RA. [18F]DCFPyL PET\/CT for imaging of prostate cancer. Nuklearmedizin. 2022;61:240-246.","journal-title":"Nuklearmedizin"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11307-021-01632-x","article-title":"Translational development of a Zr-89-labeled inhibitor of prostate-specific membrane antigen for PET imaging in prostate cancer","volume":"24","author":"V\u00e1zquez","year":"2022","unstructured":"7. V\u00e1zquez SM, Endepols H, Fischer T, Tawadros SG, Hohberg M, Zimmermanns B, Dietlein F, Neumaier B, Drzezga A, Dietlein M, Schom\u00e4cker K. Translational development of a Zr-89-labeled inhibitor of prostate-specific membrane antigen for PET imaging in prostate cancer. Mol Imaging Biol. 2022;24:115-125.","journal-title":"Mol Imaging Biol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/bjr\/tqae092","article-title":"Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands","volume":"97","author":"Naik","year":"2024","unstructured":"8. Naik M, Khan SR, Lewington V, Challapalli A, Eccles A, Barwick TD. Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands. Br J Radiol. 2024;97:1391-1404.","journal-title":"Br J Radiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"11271","DOI":"10.1038\/s41598-024-61961-z","article-title":"Dual FDG\/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT","volume":"14","author":"Rosar","year":"2024","unstructured":"9. Rosar F, Burgard C, David S, Marlowe RJ, Bartholom\u00e4 M, Maus S, Petto S, Khreish F, Schaefer-Schuler A, Ezziddin S. Dual FDG\/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT. Sci Rep. 2024;14:11271.","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1186\/s12885-024-12734-4","article-title":"Diagnostic effi-cacy of [99mTc]Tc-PSMA SPECT\/CT for prostate cancer: a meta-analysis","volume":"24","author":"Wang","year":"2024","unstructured":"10. Wang Q, Ketteler S, Bagheri S, Ebrahimifard A, Luster M, Librizzi D, Yousefi BH. Diagnostic effi-cacy of [99mTc]Tc-PSMA SPECT\/CT for prostate cancer: a meta-analysis. BMC Cancer. 2024;24:982.","journal-title":"BMC Cancer"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Aksu A, \u00c7apa Kaya G. Is SUV Corrected for lean body mass superior to SUV of body weight in 68Ga-PSMA PET\/CT? Mol Imaging Radionucl Ther. 2021;30:144-149.","DOI":"10.4274\/mirt.galenos.2021.59254"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13014-024-02483-w","article-title":"Quantitative PSMA-PET parameters in local-ized prostate cancer: prognostic and potential predictive value","volume":"19","author":"Bela Andela","year":"2024","unstructured":"12. Bela Andela S, Amthauer H, Furth C, Rogasch JM, Beck M, Mehrhof F, Ghadjar P, van den Hoff J, Klatte T, Tahbaz R, Zips D, Hofheinz F, Zschaeck S. Quantitative PSMA-PET parameters in local-ized prostate cancer: prognostic and potential predictive value. Radiat Oncol. 2024;19:97.","journal-title":"Radiat Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","unstructured":"13. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, P\u00e9rez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION investigators. lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103.","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2967\/jnumed.121.263638","article-title":"Why we did what we did: PSMA PET\/CT selection criteria for the VISION Trial","volume":"63","author":"Kuo","year":"2022","unstructured":"14. Kuo PH, Benson T, Messmann R, Groaning M. Why we did what we did: PSMA PET\/CT selection criteria for the VISION Trial. J Nucl Med. 2022;63:816-818.","journal-title":"J Nucl Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2967\/jnumed.122.264296","article-title":"Eligibility for 177Lu-PSMA therapy depends on the choice of companion diagnos-tic tracer: a comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in metastatic castration-resistant prostate cancer","volume":"64","author":"Cook","year":"2023","unstructured":"15. Cook GJR, Wong WL, Sanghera B, Mangar S, Challapalli A, Bahl A, Bassett P, Leaning D, Schmidkonz C. Eligibility for 177Lu-PSMA therapy depends on the choice of companion diagnos-tic tracer: a comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in metastatic castration-resistant prostate cancer. J Nucl Med. 2023;64:227-231.","journal-title":"J Nucl Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.semnuclmed.2024.02.007","article-title":"Prostate cancer theranostics with 177Lu-PSMA","volume":"54","author":"Ahmadzadehfar","year":"2024","unstructured":"16. Ahmadzadehfar H, Seifert R, Afshar-Oromieh A, Kratochwil C, Rahbar K. Prostate cancer theranostics with 177Lu-PSMA. Semin Nucl Med. 2024;54:581-590.","journal-title":"Semin Nucl Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","article-title":"Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard","volume":"61","author":"Kuten","year":"2020","unstructured":"17. Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, Mabjeesh NJ, Yossepowitch O, Mishani E, Even-Sapir E. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med. 2020;61:527-532.","journal-title":"J Nucl Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.euo.2022.03.004","article-title":"A systematic review of the literature","volume":"5","author":"Evangelista","year":"2022","unstructured":"18. Evangelista L, Maurer T, van der Poel H, Alongi F, Kunikowska J, Laudicella R, Fanti S, Hofman MS. [68Ga]Ga-PSMA versus [18F]PSMA positron emission tomography\/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review of the literature. Eur Urol Oncol. 2022;5:273-282.","journal-title":"Eur Urol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2022.05.010","article-title":"18F-PSMA-11 versus 68Ga-PSMA-11 posi-tron emission tomography\/computed tomography for staging and biochemical recurrence of prostate cancer: a prospective double-blind randomised cross-over trial","volume":"82","author":"De Man","year":"2022","unstructured":"19. De Man K, Van Laeken N, Schelfhout V, Fendler WP, Lambert B, Kersemans K, Piron S, Lumen N, Decaestecker K, Fonteyne V, Delrue L, De Vos F, Ost P. 18F-PSMA-11 versus 68Ga-PSMA-11 posi-tron emission tomography\/computed tomography for staging and biochemical recurrence of prostate cancer: a prospective double-blind randomised cross-over trial. Eur Urol. 2022;82:501-509.","journal-title":"Eur Urol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.3390\/jcm11175064","article-title":"Primary staging of prostate cancer patients with [18F]PSMA-1007 PET\/CT compared with [68Ga]Ga-PSMA-11 PET\/CT","volume":"11","author":"Hoffmann","year":"2022","unstructured":"20. Hoffmann MA, M\u00fcller-H\u00fcbenthal J, Rosar F, Fischer N, von Eyben FE, Buchholz HG, Wieler HJ, Schreckenberger M. Primary staging of prostate cancer patients with [18F]PSMA-1007 PET\/CT compared with [68Ga]Ga-PSMA-11 PET\/CT. J Clin Med. 2022;11:5064.","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13550-021-00845-z","article-title":"Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis","volume":"11","author":"Hober\u00fcck","year":"2021","unstructured":"21. Hober\u00fcck S, L\u00f6ck S, Borkowetz A, Sommer U, Winzer R, Z\u00f6phel K, Fedders D, Michler E, Kotzerke J, Kopka K, H\u00f6lscher T, Braune A. Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res. 2021;11:109.","journal-title":"EJNMMI Res"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Chandekar KR, Singh H, Kumar R, Kumar S, Kakkar N, Mittal BR, Singh SK. Comparison of 18 F-PSMA-1007 PET\/CT with 68 Ga-PSMA-11 PET\/CT for initial staging in intermediate- and high-risk prostate cancer. Clin Nucl Med. 2023;48:e1-e8.","DOI":"10.1097\/RLU.0000000000004430"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13550-023-00981-8","article-title":"Multiparametric dynamic whole-body PSMA PET\/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007","volume":"13","author":"Dias","year":"2023","unstructured":"23. Dias AH, Jochumsen MR, Zacho HD, Munk OL, Gormsen LC. Multiparametric dynamic whole-body PSMA PET\/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007. EJNMMI Res. 2023;13:31.","journal-title":"EJNMMI Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13550-024-01097-3","article-title":"Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET\/CT with an inter- and intrapatient based analysis","volume":"14","author":"Popescu","year":"2024","unstructured":"24. Popescu CE, Zhang B, Sartoretti T, Spielhofer N, Skawran S, Heimer J, Messerli M, Sauter A, Huellner MW, Kaufmann PA, Burger IA, Maurer A. Evaluating the biodistribution for [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET\/CT with an inter- and intrapatient based analysis. EJNMMI Res. 2024;14:36.","journal-title":"EJNMMI Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2967\/jnumed.122.264741","article-title":"Is 18F-FDG PET needed to as-sess 177Lu-PSMA therapy eligibility? A VISION-like, single-center analysis","volume":"64","author":"Seifert","year":"2023","unstructured":"25. Seifert R, Telli T, Hadaschik B, Fendler WP, Kuo PH, Herrmann K. Is 18F-FDG PET needed to as-sess 177Lu-PSMA therapy eligibility? A VISION-like, single-center analysis. J Nucl Med. 2023;64:731-737.","journal-title":"J Nucl Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/med4.70006","article-title":"Comparing the diagnostic performance of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 in PET\/CT imaging and staging of recurrent prostate cancer","volume":"3","author":"Abdi","year":"2025","unstructured":"26. Abdi N, Alsulami M, Ghaznavi H. Comparing the diagnostic performance of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 in PET\/CT imaging and staging of recurrent prostate cancer. Med Adv. 2025;3:9-19.","journal-title":"Med Adv"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40336-024-00659-8","article-title":"The clinical predictive value of radiomic features from [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET in patients with prostate cancer: a preliminary comparative study","volume":"12","author":"Pizzuto","year":"2024","unstructured":"27. Pizzuto DA, Guerreri M, Zamboglou C, Boldrini L, Gatta R, Ruggierro M, De Summa M, Caldarel-la C, Annunziata S. The clinical predictive value of radiomic features from [68Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET in patients with prostate cancer: a preliminary comparative study. Clin Transl Imaging 2024;12:629-638.","journal-title":"Clin Transl Imaging"},{"key":"ref27","unstructured":"28. (ANSM) Andsdmedpds. Protocole D'utilisation therapeutique et de Recueil D'informations ABX-PSMA-1007, 1300 MBq\/mL solution injectable, substance active: [18F]PSMA-1007. 2010. Available from: http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/extrait.php?specid= 64034289."},{"key":"ref28","unstructured":"29. Public Health Evidence Report 2307. Prostate-specific membrane antigen (PSMA) radiotracers in positron emission tomography - computed tomography (PETCT) imaging for individuals with high-risk primary or recurrent prostate cancer (adults). (2025, February). NHS England."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2967\/jnumed.122.264489","article-title":"0","volume":"64","author":"Kind","year":"2023","unstructured":"30. Kind F, Eder AC, Jilg CA, Hartrampf PE, Meyer PT, Ruf J, Michalski K. Prognostic value of tumor volume assessment on PSMA PET After 177Lu-PSMA radioligand therapy evaluated by PSMA PET\/ct consensus statement and RECIP 1.0. J Nucl Med. 2023;64:605-610.","journal-title":"J Nucl Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"0","volume":"50","author":"Fendler","year":"2023","unstructured":"31. Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Sch\u00f6der H, Wan S, Wester HJ, Hope TA, Herrmann K. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466-1486.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s13139-024-00891-0","article-title":"Harnessing terbium radioisotopes for clinical advancements: a systematic review","volume":"59","author":"Abdlkadir","year":"2025","unstructured":"32. Abdlkadir AS, Rosar F, Jalilian A, Moghrabi S, Al-Balooshi B, Rabei O, Kairemo K, Al-Ibraheem A. Harnessing terbium radioisotopes for clinical advancements: a systematic review. Nucl Med Mol Imaging. 2025;59:50-61.","journal-title":"Nucl Med Mol Imaging"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","unstructured":"33. Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, Davis C, Eiber M, Hekim-soy T, Knoesen O, Kratochwil C, Lenzo NP, Mahapane J, Maserumule LC, Mdlophane AH, Mo-koala KMG, Ndlovu H, Pant V, Rathke H, Reed J, Sen IB, Singh A, Sood A, Tauber R, Thakral P, Yadav MP, Morgenstern A. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175-183.","journal-title":"Lancet Oncol"}],"container-title":["Molecular Imaging and Radionuclide Therapy"],"original-title":[],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:13:47Z","timestamp":1770185627000},"score":1,"resource":{"primary":{"URL":"https:\/\/mirt.tsnmjournals.org\/articles\/quantitative-characterization-of-lesssupgreater18lesssupgreaterf-psma-1007-and-lesssupgreater68lesssupgreatergaga-psma-11-pet-ct-imaging-in-suspected-prostate-cancer-a-single-centre-experience\/doi\/mirt.galenos.2025.92259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":33,"URL":"https:\/\/doi.org\/10.4274\/mirt.galenos.2025.92259","relation":{},"ISSN":["2146-1414","2147-1959"],"issn-type":[{"value":"2146-1414","type":"print"},{"value":"2147-1959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}